| Similar Articles |
|---|
 |
The Motley Fool
January 26, 2010
Dave Mock |
A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars.   |
Bio-IT World
Jul/Aug 2006
Robert M. Frederickson |
Tests for Hospital-Acquired Infections Tests for pathogens increasingly rely on genomic methods that identify specific genetic signatures of bacteria or viruses. Rapid detection of other pathogens also provides the potential for significant impact on the healthcare industry. |
Chemistry World
October 29, 2015
Anthony King |
Poor diagnostics hinder battle against antibiotic resistance The tools used to diagnose bacterial infections have barely improved since the 1940s. |
The Motley Fool
February 28, 2008
Brian Lawler |
Third Wave Making Tiny Ripples Small molecular-diagnostics developer Third Wave Technologies could be poised for big returns. |
BusinessWeek
January 19, 2004 |
Sniffing For Anthrax Little-known Cepheid has caught the eye not only of traders but also of long-term big investors. |
The Motley Fool
September 26, 2006
Ralph Casale |
Biotech's Distant Star Cepheid still isn't a profitable company, but strong sales growth should continue. This is a high risk holding until it demonstrates profitability and its instruments are widely adopted. |
Pharmaceutical Executive
September 1, 2010 |
The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development. |
Wired
July 24, 2007
Thomas Goetz |
The Ultimate Diagnostic Device (By the Way, You've Got Drug-Resistant TB!) The CDC's goal of a tuberculosis-free society grew short due to the development of drug-resistant strains. But new standards for detection are in the works. |
Bio-IT World
November 14, 2003
Elizabeth Gardner |
Ultimate Analysis With the necessary tools at hand, the race is on to build -- and market -- the first affordable, portable, fully functional DNA analyzer. Is the world ready? |
The Motley Fool
August 17, 2007
Brian Orelli |
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. |
The Motley Fool
May 9, 2007
Brian Lawler |
Diagnosing Dendreon Postmortem The FDA issues an approvable letter for Dendreon's top compound. Investors, take note. |
The Motley Fool
December 22, 2003
Alyce Lomax |
Losing Faith in Inspire Delay for its dry-eye treatment leaves investors uninspired. |
The Motley Fool
May 30, 2008
Brian Orelli |
No Love for Antibiotics From the FDA Wyeth gets an approvable letter for its antibiotic Tygacil. |
The Motley Fool
January 14, 2008
Brian Lawler |
Score One for Dendreon and Disclosure A prestigious journal supports Dendreon's potential prostate cancer treatment, and makes a compelling case for more FDA disclosure. |
Food Engineering
February 11, 2009 |
FDA releases recall tool: Try it out! FDA's recall tool provides up-to-date info on Salmonella recalls |
Food Processing
February 2011
David Joy |
7 Things You Should Know About The New Food Safety Law Considered a win for consumers, the new law will have varying effects on food & beverage processors. |
Food Processing
January 2013
Eric Lindstrom |
Food Safety Regulatory Outlook for 2013 Similar to 2012, the FDA will continue to evolve and enact the Food Safety Modernization Act. |
The Motley Fool
November 14, 2007
Brian Lawler |
Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years. |
Food Processing
February 2012
Eric Lindstrom |
The FDA's Food Safety Outlook for 2012 The FDA will be consumed with implementing the Food Safety Modernization Act, with July as a particularly important month. |
HBS Working Knowledge
September 24, 2007
Sean Silverthorne |
The FDA: What Will the Next 100 Years Bring? The challenge for FDA leaders is to maintain morale and focus, and to back up decisions with solid data on benefits and risks to different consumer populations. |
Pharmaceutical Executive
January 1, 2006
Kenneth I. Kaitin |
Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do. |
Pharmaceutical Executive
June 1, 2009
Jill Wechsler |
A Bigger, Bolder Agency FDA is seeking more resources to support compliance and oversight. |
The Motley Fool
March 3, 2009
Brian Orelli |
A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals. |
Food Processing
October 2008
Diane Toops |
A Conversation with Food Safety Czar David W.K. Acheson A exclusive conversation with `food safety czar' David W.K. Acheson, FDA's Associate Commissioner for Foods. |
Pharmaceutical Executive
February 1, 2012
Jennifer Ringler |
Industry Trees are Falling, But is FDA Around to Hear? Experts weigh in on FDA's long-awaited social media guidelines. |
CIO
March 15, 2006
Allan Holmes |
Rx for Risk As it revamps its workflow processes, the FDA is relying on technology to reduce the risk that unsafe substances will get into the market. |
IndustryWeek
October 19, 2011 |
FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies? |
Pharmaceutical Executive
October 1, 2006
George Koroneos |
Pharm Exec Q&A: Inside View The Union of Concerned Scientists made revelations about the FDA's own scientific culture. Here, Francesca Grifo, director of scientific integrity program at UCS, talks about the findings. |
